Background. We report the development, validation, and implementation of an open-source population-based outcomes model of chronic obstructive pulmonary disease (COPD) for Canada. Methods. Evaluation Platform in COPD (EPIC) is a discrete-event simulation model of Canadians 40 years of age or older. Three core features of EPIC are its open-population design (incorporating projections of future population growth, aging, and smoking trends), its incorporation of heterogeneity in lung function decline and burden of exacerbations, and its modeling of the natural history of COPD from inception. Multiple original data analyses, as well as values reported in the literature, were used to populate the model. Extensive face validity and internal and external validity evaluations were performed. Results. The model was internally validated on demographic projections, mortality rates, lung function trajectories, COPD exacerbations, costs and health state utility values, and stability of COPD prevalence over time within strata of risk factors. In external validation, it moderately overestimated the rate of overall exacerbations in 2 independent trials but generated consistent estimates of rate of severe exacerbations and mortality. Limitations. In its current version, EPIC does not consider uncertainty in the evidence. Several components such as additional (e.g., environmental and occupational) risk factors, treatment, symptoms, and comorbidity will have to be added in future iterations. Predictive validity of EPIC needs to be examined prospectively against future empirical studies. Conclusions. EPIC is the first multipurpose, open-source, outcome- and policy-focused model of COPD for Canada. Platforms of this type have the capacity to be iteratively updated to incorporate the latest evidence and to project the outcomes of many different scenarios within a consistent framework.
SorianoJBAbajobirAAAbateKH, et al. Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Respir Med. 2017;5(9):691–706.
EvansJChenYCampPGBowieDMMcRaeL.Estimating the prevalence of COPD in Canada: Reported diagnosis versus measured airflow obstruction. Health Rep. 2014;25(3):3–11.
4.
AaronSD.Management and prevention of exacerbations of COPD. BMJ. 2014;349:g5237.
5.
CampPLevyR.A snapshot of chronic obstructive pulmonary disease in British Columbia and Canada. BC Med J. 2008;50(2):80.
6.
KhakbanASinDDFitzGeraldJM, et al. Ten-year trends in direct costs of COPD: a population based study. Chest. 2015;148(3):640–6.
7.
Global Initiative for Chronic Obstructive Lung Disease (GOLD)2017. Global strategy for the diagnosis, management and prevention of COPD. Available from: http://goldcopd.org
8.
American Thoracic Society/European Respiratory Society Task Force. Standards for the diagnosis and management of patients with COPD. Version 1.2. Available from: http://www.thoracic.org/clinical/copd-guidelines/
9.
Gruffydd-JonesKLoveridgeC.The 2010 NICE COPD guidelines: how do they compare with the GOLD guidelines?Prim Care Respir J. 2011;20(2):199–204.
10.
ScotlandGBryanS.Why do health economists promote technology adoption rather than the search for efficiency? A proposal for a change in our approach to economic evaluation in health care. Med Decis Making. 2017;37(2):139–47.
11.
BuxtonMJDrummondMFVan HoutBA, et al. Modelling in economic evaluation: an unavoidable fact of life. Health Econ. 1997;6(3):217–27.
12.
BelleteBCoberlyJBarnesGL, et al. Evaluation of a whole-blood interferon-gamma release assay for the detection of Mycobacterium tuberculosis infection in 2 study populations. Clin Infect Dis. 2002;34:1449–56.
13.
NielsenRJohannessenABenediktsdottirB, et al. Present and future costs of COPD in Iceland and Norway: results from the BOLD study. Eur Respir J. 2009;34(4):850–7.
14.
NajafzadehMMarraCALyndLD, et al. Future impact of various interventions on the burden of COPD in Canada: a dynamic population model. PLoS ONE. 2012;7(10):e46746.
15.
OostenbrinkJBRutten-van MölkenMPMHMonzBUFitzGeraldJM.Probabilistic Markov model to assess the cost-effectiveness of bronchodilator therapy in COPD patients in different countries. Value Health. 2005;8:32–46.
16.
TappendenPChilcottJBrennanASquiresHStevensonM.Whole disease modeling to inform resource allocation decisions in cancer: a methodological framework. Value Health. 2012;15(8):1127–36.
17.
AfzaliHHAKarnonJMerlinT. Improving the accuracy and comparability of model-based economic evaluations of health technologies for reimbursement decisions: a methodological framework for the development of reference models. Med Decis Making. 2013;33(3):325–32.
18.
HoogendoornMFeenstraTLAsukaiY, et al. Cost-effectiveness models for chronic obstructive pulmonary disease: cross-model comparison of hypothetical treatment scenarios. Value Health. 2014;17(5):525–36.
19.
HoogendoornMRutten-van MölkenMPMHHoogenveenRT, et al. A dynamic population model of disease progression in COPD. Eur Respir J. 2005;26(2):223–33.
20.
BirchSGafniA.Cost effectiveness/utility analyses: do current decision rules lead us to where we want to be?J Health Econ. 1992;11(3):279–96.
21.
RobertsMRussellLBPaltielAD, et al. Conceptualizing a model: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force–2. Value Health. 2012;15(6):804–11.
22.
BriggsADMWolstenholmeJBlakelyTScarboroughP. Choosing an epidemiological model structure for the economic evaluation of non-communicable disease public health interventions. Popul Health Metr. 2016;14:17.
23.
HennessyDAFlanaganWMTanuseputroP, et al. The Population Health Model (POHEM): an overview of rationale, methods and applications. Popul Health Metr. 2015;13:24.
24.
SwanneyMPRuppelGEnrightPL, et al. Using the lower limit of normal for the FEV1/FVC ratio reduces the misclassification of airway obstruction. Thorax. 2008;63(12):1046–51.
25.
TanWCBourbeauJHernandezP, et al. Canadian prediction equations of spirometric lung function for Caucasian adults 20 to 90 years of age: results from the Canadian Obstructive Lung Disease (COLD) study and the Lung Health Canadian Environment (LHCE) study. Can Respir J. 2011;18(6):321–6.
26.
FreemanJHutchisonGB.Prevalence, incidence and duration. Am J Epidemiol. 1980;112(5):707–23.
27.
BourbeauJTanWCBenedettiA, et al. Canadian Cohort Obstructive Lung Disease (CanCOLD): Fulfilling the need for longitudinal observational studies in COPD. COPD. 2014;11(2):125–32.
28.
ZafariZSinDDPostmaDS, et al. Individualized prediction of lung-function decline in chronic obstructive pulmonary disease. CMAJ. 2016;188(14):1004–11.
29.
HankinsonJLOdencrantzJRFedanKB.Spirometric reference values from a sample of the general U.S. population. Am J Respir Crit Care Med. 1999;159(1):179–87.
30.
AaronSDFergussonDMarksGB, et al. Counting, analysing and reporting exacerbations of COPD in randomised controlled trials. Thorax. 2008;63(2):122–8.
31.
HoogendoornMFeenstraTLHoogenveenRTAlMMölkenMR.Association between lung function and exacerbation frequency in patients with COPD. Int J Chron Obstruct Pulmon Dis. 2010;5:435–44.
32.
AlbertRKConnettJBaileyWC, et al. Azithromycin for prevention of exacerbations of COPD. N Engl J Med. 2011;365(8):689–98.
33.
HurstJRVestboJAnzuetoA, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010;363(12):1128–38.
34.
SadatsafaviMSinDDZafariZ, et al. The association between rate and severity of exacerbations in chronic obstructive pulmonary disease: an application of a joint frailty-logistic model. Am J Epidemiol. 2016;184(9):681–9.
SpencerMBriggsAGrossmanRRanceL.Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease. Pharmacoeconomics. 2005;23(6):619–37.
37.
MittmannNKuramotoLSeungSJHaddonJMBradley-KennedyCFitzGeraldJM.The cost of moderate and severe COPD exacerbations to the Canadian healthcare system. Respir Med. 2008;102(3):413–21.
R Core Team. R: a language and environment for statistical computing. Available from: https://www.R-project.org/
40.
EddyDMHollingworthWCaroJJ, et al. Model transparency and validation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force–7. Value Health. 2012;15(6):843–50.
41.
CalverleyPMAAndersonJACelliB, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356(8):775–89.
42.
TashkinDPCelliBSennS, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008;359(15):1543–54.
43.
AsukaiYBaldwinMFonsecaTGrayAMungapenLPriceD.Improving clinical reality in chronic obstructive pulmonary disease economic modelling: development and validation of a micro-simulation approach. Pharmacoeconomics. 2013;31(2):151–61.
44.
BorgSEricssonAWedzichaJ, et al. A computer simulation model of the natural history and economic impact of chronic obstructive pulmonary disease. Value Health. 2004;7(2):153–67.
45.
BriggsAHBakerTRisebroughNA, et al. Development of the Galaxy chronic obstructive pulmonary disease (COPD) model using data from ECLIPSE: internal validation of a linked-equations cohort model. Med Decis Making. 2017;37(4):469–80.
46.
MennPLeidlRHolleR.A lifetime Markov model for the economic evaluation of chronic obstructive pulmonary disease. Pharmacoeconomics. 2012;30(9):825–40.
47.
SamyshkinYSchluneggerMHaefligerSLedderhoseSRadfordM.Cost-effectiveness of roflumilast in combination with bronchodilator therapies in patients with severe and very severe COPD in Switzerland. Int J Chron Obstruct Pulmon Dis. 2013;8:79–87.
48.
MenziesNASoetemanDIPandyaAKimJJ.Bayesian methods for calibrating health policy models: a tutorial. Pharmacoeconomics. 2017;35(6):613–24.
49.
ZafariZBryanSSinDDConteTKhakbanRSadatsafaviM.A systematic review of health economics simulation models of chronic obstructive pulmonary disease. Value Health. 2017;20(1):152–62.
50.
HoogendoornMFeenstraTLAsukaiY, et al. Patient heterogeneity in health economic decision models for chronic obstructive pulmonary disease: are current models suitable to evaluate personalized medicine?Value Health. 2016;19(6):800–10.
51.
HoogendoornMFeenstraTLAsukaiY, et al. External validation of health economic decision models for chronic obstructive pulmonary disease (COPD): report of the third COPD modeling meeting. Value Health. 2017;20(3):397–403.
52.
VestboJAndersonWCoxsonHO, et al. Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points (ECLIPSE). Eur Respir J. 2008;31(4):869–73.
53.
TabbererMGonzalez-McQuireSMuellerovaH, et al. Development of a conceptual model of disease progression for use in economic modeling of chronic obstructive pulmonary disease. Med Decis Making. 2017;37(4):440–52.
54.
FlattetYGarinNSerratriceJPerrierAStirnemannJCarballoS.Determining prognosis in acute exacerbation of COPD. Int J Chron Obstruct Pulmon Dis. 2017;12:467–75.
55.
ChapmanKRBourbeauJRanceL.The burden of COPD in Canada: results from the Confronting COPD survey. Respir Med. 2003;97(Suppl C):S23–31.
Rutten-van MölkenMPMHHoogendoornMLamersLM.Holistic preferences for 1-year health profiles describing fluctuations in health: the case of chronic obstructive pulmonary disease. Pharmacoeconomics. 2009;27(6):465–77.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
